Helus Pharma Founders Hand Over the Reins as Investors Weigh a 2026 Depression Readout
Published on 11/02/2026 at 17:10 | Editorial boerse-global.de
Helus Pharma has reshuffled its leadership, confirming that co-founders Eric So and Paul Glavine stepped down from their executive and advisory roles on 27 October. Neither man has left the board. Mark Lawson, previously a board member, took over as independent chair of the supervisory body with immediate effect, and So was additionally named chairman emeritus. The company disclosed the changes in a mandatory Form 6-K filing.
The distinction matters: the shake-up touches the founders' operational and consulting duties, not their seats on the board. Investors nonetheless marked the stock down, with the shares falling 7.2% to USD 9.83 on the day.
That slide stands apart from the broader drift in the stock. On the preceding Friday, Helus Pharma closed at USD 10.60, a decline of 1.1%. No causal link between that move and the leadership transition has been established.
Should investors sell immediately? Or is it worth buying Helus Pharma Inc.?
Clinical Calendar Takes Centre Stage
With the personnel news digested, attention is shifting back to the drug pipeline. Helus Pharma used the same announcement to reaffirm the expected timing for the headline results of its Phase 3 APPROACH study, which is testing the candidate HLP003 in major depressive disorder. Summary data are still slated for the fourth quarter of 2026.
That timeline was already restated on 21 October, when the company walked investors through its clinical programmes. The earlier event was a confirmation of the expected release date — not the unveiling of Phase 3 data.
A second programme is moving on a separate track. Helus Pharma expects to launch the next Phase 2 trial of HLP004 in the first quarter of 2027, evaluating the candidate as a monotherapy for generalised anxiety disorder. For HLP004, the date refers to the start of the study, whereas the APPROACH schedule concerns the publication of results.
Wells Fargo Lifts Its Target
Sell-side sentiment has been moving in the opposite direction to the share price. Wells Fargo analyst Benjamin Burnett raised his price target to USD 22 from USD 16 on 22 October, according to media reports, while keeping his "Overweight" rating on the stock.
Ad
Helus Pharma Inc. Stock: New Analysis - 2 November
Fresh Helus Pharma Inc. information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
